GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Shiller PE Ratio

Kaken Pharmaceutical Co (TSE:4521) Shiller PE Ratio : 9.52 (As of May. 05, 2025)


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Shiller PE Ratio?

As of today (2025-05-05), Kaken Pharmaceutical Co's current share price is 円4072.00. Kaken Pharmaceutical Co's E10 for the quarter that ended in Sep. 2024 was 円427.55. Kaken Pharmaceutical Co's Shiller PE Ratio for today is 9.52.

The historical rank and industry rank for Kaken Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:

TSE:4521' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.02   Med: 11.6   Max: 22.05
Current: 9.52

During the past years, Kaken Pharmaceutical Co's highest Shiller PE Ratio was 22.05. The lowest was 8.02. And the median was 11.60.

TSE:4521's Shiller PE Ratio is ranked better than
88.97% of 526 companies
in the Drug Manufacturers industry
Industry Median: 24.365 vs TSE:4521: 9.52

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Sep. 2024 was 円330.910. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is 円427.55 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kaken Pharmaceutical Co Shiller PE Ratio Historical Data

The historical data trend for Kaken Pharmaceutical Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Shiller PE Ratio Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.89 11.49 10.04 9.42 8.67

Kaken Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.40 8.67 9.63 8.94 -

Competitive Comparison of Kaken Pharmaceutical Co's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Shiller PE Ratio falls into.


;
;

Kaken Pharmaceutical Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Kaken Pharmaceutical Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=4072.00/427.55
=9.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Kaken Pharmaceutical Co's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=330.91/108.9000*108.9000
=330.910

Current CPI (Sep. 2024) = 108.9000.

Kaken Pharmaceutical Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 95.700 97.900 106.453
201503 60.758 97.900 67.585
201506 152.090 98.400 168.319
201509 149.251 98.500 165.009
201512 184.687 98.100 205.020
201603 24.369 97.900 27.107
201606 140.050 98.100 155.468
201609 136.454 98.000 151.631
201612 157.876 98.400 174.723
201703 98.700 98.100 109.566
201706 133.810 98.500 147.938
201709 133.750 98.800 147.423
201712 148.500 99.400 162.693
201803 54.168 99.200 59.465
201806 100.160 99.200 109.954
201809 120.680 99.900 131.552
201812 136.000 99.700 148.550
201903 88.826 99.700 97.023
201906 121.650 99.800 132.742
201909 120.910 100.100 131.539
201912 154.110 100.500 166.991
202003 98.054 100.300 106.461
202006 98.180 99.900 107.025
202009 87.970 99.900 95.895
202012 96.540 99.300 105.873
202103 64.486 99.900 70.296
202106 87.780 99.500 96.073
202109 88.460 100.100 96.237
202112 93.170 100.100 101.361
202203 -18.430 101.100 -19.852
202206 76.910 101.800 82.274
202209 81.430 103.100 86.011
202212 84.970 104.100 88.888
202303 -98.978 104.400 -103.244
202306 66.990 105.200 69.346
202309 41.190 106.200 42.237
202312 68.841 106.800 70.195
202403 35.570 107.200 36.134
202406 46.320 108.200 46.620
202409 330.910 108.900 330.910

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kaken Pharmaceutical Co  (TSE:4521) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Kaken Pharmaceutical Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co Headlines

No Headlines